Effect of dupilumab on severe exacerbations and lung function in patients with baseline blood eosinophils =500 cells/µL

K. Rabe (Grosshansdorf, Germany), I. Pavord (Oxford, United Kingdom), M. Castro (Kansas City, United Kingdom), N. Daizadeh (Cambridge, United States of America), B. Ortiz (Tarrytown, United States of America), R. Johnson (Bridgewater, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America)

Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Session: Management of allergy, asthma and COPD
Session type: E-poster session
Number: 234
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Rabe (Grosshansdorf, Germany), I. Pavord (Oxford, United Kingdom), M. Castro (Kansas City, United Kingdom), N. Daizadeh (Cambridge, United States of America), B. Ortiz (Tarrytown, United States of America), R. Johnson (Bridgewater, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America). Effect of dupilumab on severe exacerbations and lung function in patients with baseline blood eosinophils =500 cells/µL. 234

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: